Form 4: BioAge Labs Director Acquires Stock Options
SEC Form 4 Filing
Michael H. Davidson, a director at BioAge Labs, acquired stock options, as reported in a recent SEC filing.
Summary
- Michael H. Davidson, a director of BioAge Labs, filed a Form 4 with the SEC.
- The filing reports the acquisition of stock options.
- Davidson acquired 15,000 stock options with an exercise price of $18 on September 25, 2024.
- He also acquired 33,986 stock options with an exercise price of $8.39 on March 26, 2024.
- The 15,000 options vest on the earlier of the next annual meeting or one year from the grant date.
- The 33,986 options vest monthly over 36 months, starting April 26, 2024.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing detailing stock option acquisitions by a company director. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. This provides transparency to the market.
Stakeholder Impact
- The acquisition of stock options by a director can be seen as a positive sign, aligning the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/26/2024 | Acquisition of 33,986 stock options at $8.39. |
| 04/26/2024 | First tranche vesting date for 33,986 options. |
| 09/25/2024 | Acquisition of 15,000 stock options at $18. |
| 09/24/2034 | Expiration date for 15,000 stock options. |
| 03/25/2034 | Expiration date for 33,986 stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.